The firm's liquidity is under pressure as the quarterly free cash flow deficit reached $18.9 million in 2026Q1, driven by intensifying clinical trial requirements.
Aardvark Therapeutics, Inc. Common Stock (AARD) cash flow statement — 4-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 |
|---|
| Cash from Operations | -69.41M | -54.17M | -18.09M | -5.82M | -10.54M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | -599.32% | -199.51% | -210.56% | 44.76% | - |
| Net Income | -69.89M | -57.59M | -20.59M | -7.21M | -13.56M |
| Depreciation & Amortization | -87K | -1.31M | 16K | 97K | 110K |
| Stock-Based Compensation | 3.95M | 3.95M | 439K | 313K | 412K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 397K | 421K | 473K | 1.05M | 3.81M |
| Working Capital Changes | -3.78M | 356K | 1.57M | -81K | -1.31M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -2.97M | 239K | 798K | 776K | 31K |
| Cash from Investing | 116.55M | -49.67M | -12M | 0 | -1M |
| Capital Expenditures | -4K | -95K | -109K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -1M |
| Cash from Financing | 711K | 89.25M | 81.99M | 0 | 225K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | -1M |
| Equity Issued (Net) | 711K | 89.25M | 85.33M | 0 | 225K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -3.34M | 0 | 1M |
| Net Change in Cash | 47.85M | -14.59M | 51.91M | -5.82M | -11.32M |
| Free Cash Flow | -69.41M | -54.27M | -18.2M | -5.82M | -10.54M |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | -110.24% | -198.24% | -212.43% | 44.76% | - |
| FCF per Share | -3.18 | -2.49 | -0.84 | -0.27 | -0.49 |
| FCF Conversion (FCF/Net Income) | 0.99x | 0.94x | 0.88x | 0.81x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying AARD stock.
Aardvark Therapeutics, Inc. Common Stock (AARD) generated $-54.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Aardvark Therapeutics, Inc. Common Stock (AARD) reported negative free cash flow of $54.3M in 2025, indicating capital requirements exceeded cash from operations.
Aardvark Therapeutics, Inc. Common Stock (AARD) spent $0.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Clinical trial funding shortfall
Metrics are mathematically derived from official filings.
Accelerating Cash Burn Profile
As reported in recent financial statements, Aardvark's quarterly free cash flow deficit has expanded significantly, reaching $18.9 million in 2026Q1, which highlights the intensifying capital requirements as the company progresses its lead metabolic candidate through the critical Phase III clinical trial execution phase.
The trajectory of free cash flow reflects a company in a pure capital consumption phase, with deficits widening in lockstep with clinical trial milestones. Investors should monitor this trend closely, as the lack of revenue generation means that every dollar of cash burn directly reduces the runway available for regulatory success.
Operating Cash Flow Quality Divergence
Based on the provided cash flow data, the OCF/NI ratio has fluctuated between 0.57 and 1.22 over the last ten quarters, suggesting that non-cash adjustments and working capital volatility are significantly distorting the relationship between reported net losses and actual cash outflows from core operations.
The inconsistency in the conversion ratio implies that the company's net income is not a reliable proxy for cash consumption, largely due to the impact of stock-based compensation and periodic working capital swings. This divergence warrants further investigation into how much of the reported loss is truly representative of the underlying cash-based operational expenses.
Working Capital Volatility Risks
According to quarterly filings, working capital changes have swung from a $4.4 million inflow in 2025Q2 to a $999,000 outflow in 2025Q3, indicating that the company's cash position is highly sensitive to the timing of clinical trial payments and vendor settlement cycles.
These fluctuations suggest that management is actively managing liquidity through the timing of payables, which can mask the true underlying burn rate in any single quarter. Analysts should look past these quarterly swings to assess the structural cash requirements of the ongoing Phase III program.
Obscured Clinical Execution Costs
Financial data indicates that stock-based compensation reached $2.0 million in 2026Q1, which effectively obscures the true cash cost of talent retention while simultaneously diluting existing shareholders to preserve the company's limited $47.05 million cash reserve for essential clinical trial activities.
The reliance on non-cash compensation suggests a strategic effort to conserve liquid assets, yet this practice creates a disconnect between accounting expenses and actual cash preservation. Investors should be wary of how these adjustments impact the long-term equity value as the company approaches its next major funding inflection point.